A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndrome

Leukemia

Volumn 18, Issue 3, 2004, Pages 460-465

  Stadler, M ^a   Germing, U ^b   Kliche, K O ^c   Josten, K M ^d   Kuse, R ^e   Hofmann, W K ^f   Schrezenmeier, H ^g   Novotny, J ^h   Andres, O ⁱ   Eimermacher, H ^j   Verbeek, W ^a   Kreipe, H H ^a   Heimpel, H ^k   Aul, C ^l   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^e ST GEORGE HOSPITAL   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g FREIE UNIVERSITÄT BERLIN   (Germany)

^h UNIVERSITY OF DUISBURG ESSEN   (Germany)

ⁱ Klinikum Sudstadt   (Germany)

^j St Marien Hospital   (Germany)

^k UNIVERSITY OF ULM   (Germany)

^l ST JOHANNES HOSPITAL   (Germany)

more..

Author keywords

Antithymocyte globulin; Immune modulation; Myelodysplastic syndromes

Indexed keywords

AMIFOSTINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CYCLOSPORIN A; CYTOKINE; HORMONE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; RABBIT ANTISERUM; THALIDOMIDE; THYMOCYTE ANTIBODY; VITAMIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BRAIN INFECTION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE DURATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HORSE; HUMAN; IMMUNOMODULATION; INFECTION; LUNG EMBOLISM; MALE; MUCORMYCOSIS; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NOSE INFECTION; PARALYTIC ILEUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; RISK ASSESSMENT; SERUM SICKNESS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; ANIMAL; IMMUNOLOGY; MIDDLE AGED; RABBIT; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; FEMALE; HORSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; RABBITS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1542608520     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403239     Document Type: Article

References (30)

1. Ganser A, Hoelzer D. Clinical course of myelodysplastic syndromes. Hematol Oncol Clin N Am 1992; 6: 607-618.
2. Ganser A, Ottmann O, Seipelt G, Lindemann A, Hess U, Geissler G et al. Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia 1993; 7: 696-701.
3. Raza A, Mundle S, Shetty V, Alvi S, Chepra H, Span L et al. Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines. Int J Hematol 1996; 63: 265-278.
4. Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leukemia Lymphoma 2000; 37: 405-414.
5. Smith MA, Smith JG. The occurrence, subtype and significance of hematopoietic inhibitory T cells (HIT cells) in myelodysplasia: An in vitro study. Leukemia Res 1991; 5: 597-601.
6. Sugarawa T, Endo K, Shishido T, Sato A, Kameoka J, Fukuhara O et al. T-cell mediated inhibition of erythropoiesis in myelodysplastic syndromes. Am J Hematol 1992; 41: 304-305.
7. Marsh JCW, Hows JM, Bryett KA, Al-Hashimi S, Fairhead SM, Gordon-Smith EC. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood 1987; 70: 1046-1052.
8. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991; 324: 1297-1304.
9. Raefsky EL, Gascon P, Gratwohl A, Speck B, Young NS. Biological and immunological characterization of ATG and ALG. Blood 1986; 68: 712-719.
10. Tichelli A, Gratwohl A, Wuersch A, Nissen C, Speck B. Antilymphocyte globulin for myelodysplastic syndrome? Br J Haematol 1988; 68: 139-140.
11. Sulecki M, Shadduck RK, Zeigler Z. Anti-thymocyte globulin for hypoplastic myelodysplastic syndrome. Blood 1988; 72: 229.
12. Miescher PA, Favre H, Beris P. Autoimmune myelodysplasias. Semin Hematol 1991; 28: 322-330.
13. Mineishi S, Filippa D, Childs B, Castro-Melaspina H. Hypoplastic myelodysplastic syndrome (MDS): Clinical, hematologic, and pathologic observations in 36 cases. Blood 1994; 84: 1245.
14. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndromes. Cancer 1997; 79: 1548-1551.
15. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699-705.
16. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156-163.
17. Jonásová A, Neuwirtová R, Cermák J, Vozobulová V, Mociková K, Sisková M et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304-309.
18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
19. Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model. Br J Haematol 1997; 99: 344-351.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Luberiza F, Maciejewski JP et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplasic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100: 1570-1574.
22. Harris NL, Jaffe ES, Diebold J, Flandrin G, Müller-Hermelink HK, Vardiman J et al. The World Health Organization classification of the hematologic malignancies. Report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
23. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International prognostic scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
24. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100: 3639-3645.
25. Aivado M, Rong A, Stadler M, Germing U, Giagounidis A, Strupp C et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk MDS patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 2002; 68: 210-216.
26. Killick S, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC et al. A pilot study of antithymocyte globulin (ATG) in the treatment of 'low-risk' myelodysplasia. Br J Haematol 2003; 120: 679-684.
27. Asano Y, Maeda M, Uchida N, Yokoyama T, Osaki K, Shimoda K et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 2001; 80: 634-638.
28. Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndromes. Blood 2003; 101: 2156-2158.
29. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
30. Aul C, Giagounidis A, Germing U, Ganser A. Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 2002; 81: 485-497.